Received Mar 23, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | Unknown | — |
The patient took second dose of Vivotif on the second day; The patient took antibiotic Doxycycline and Vivotif in the same period; Case reference number US-BN-2024-002333 is a spontaneous case initially received from consumer via agency (reference number USBAV24-1933) on 09-Aug-2024 and concerns a male patient of unspecified age. The patient's medical history details were not provided. The patient's procedure included surgery. The patient's co-suspect medications included doxycycline (brand name: unknown). On an unspecified date, the patient took the first dose of Vivotif (batch number: unknown), at unknown dose, orally, for typhoid immunization. As reported, the patient had been in the middle of taking antibiotic doxycycline (explicitly coded as 'Labelled drug-drug interaction medication error') On an unspecified date, reported as on the second day, the patient took the second dose of Vivotif (batch number: unknown), at unknown dose, orally (explicitly coded as 'Inappropriate schedule of vaccine administered'). *Patient was advised from doctor to stop taking Vivotif and to wait two weeks after completion of doxycycline treatment. * On an unspecified date, unknown amount of time after the second dose, patient began the Vivotif regimen again as per doctor's instructions (batch number: unknown), at unknown dose, via unknown route. As reported after waiting one week beyond the period that the doxycycline had left the system. *On an unspecified dates, as reported the patient successfully completed Vivotif treatment (number of doses which patient took to be confirmed). * At the time of the *follow up report, the patient did not experience any adverse event due to Vivotif vaccine, since it was reported patient's health was well. * All follow-up information is blended into the case narrative above, with the latest information presented between asterisks (*). Follow up information received from a consumer on 23-Aug-2024: New information included confirmation on the Vivotif usage and dosage information. Follow up information received from a consumer on 19-Sep-2024: New information included confirmation that the patient completed Vivotif treatment and patient did not experience any adverse event due to Vivotif vaccine. Non-significant follow-up was downloaded from VAERS on 09-May-2025 included new reference number. Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20240812-3b2861 to US-BAVARIAN NORDIC A/S-US-BN-2024-002333, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: A male patient received the first two doses of Vivotif on two consecutive days, which is considered inappropriate schedule of vaccination. Furthermore, the patient had been receiving co-suspect doxycycline (which is considered labelled drug-drug interaction (DDI) medication error). Inappropriate schedule of vaccine administered and labelled DDI error are listed per company conventions. The patient did not experience any adverse event due to Vivotif vaccine. Patient had undergone a surgery which required doxycycline use. The events are not related to Vivotif, but to human error. The case is non-serious.; Sender's Comments: A male patient received the first two doses of Vivotif on two consecutive days, which is considered inappropriate schedule of vaccination. Furthermore, the patient had been receiving co-suspect doxycycline (which is considered labelled drug-drug interaction (DDI) medication error). Inappropriate schedule of vaccine administered and labelled DDI error are listed per company conventions. The patient did not experience any adverse event due to Vivotif vaccine. Patient had undergone a surgery which required doxycycline use. The events are not related to Vivotif, but to human error. The case is non-serious.
Medical History/Concurrent Conditions: Surgery
DOXYCYCLINE